SCHEMBL4770836

SCHEMBL4770836

COc1cccc(S(=O)(=O)N(C(=O)C(CC(C)C)NC(=O)c2cc3cc(OC)ccc3o2)[C@H]2CCCNCC2=O)c1

nearest known ligand 0.51

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 14/20 0.51
TAS1R1 Q7RTX1 14/20 0.51
BCAT1 P54687 1/20 0.40
CTSK P43235 5/20 0.38
CTSL P07711 2/20 0.37
CTSB P07858 2/20 0.37
CTSS P25774 2/20 0.37
CTSV O60911 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770834 1.00 TAS1R3 (0.51) TAS1R3TAS1R1BCAT1CTSKCTSL
SCHEMBL4761901 0.95 TAS1R3 (0.48) TAS1R3TAS1R1BCAT1CTSKCTSL
SCHEMBL4761899 0.95 TAS1R3 (0.48) TAS1R3TAS1R1BCAT1CTSKCTSL
SCHEMBL4762061 0.95 TAS1R3 (0.47) TAS1R3TAS1R1CTSKCTSLCTSB
SCHEMBL4762063 0.95 TAS1R3 (0.47) TAS1R3TAS1R1CTSKCTSLCTSB
SCHEMBL6586348 0.94 TAS1R3 (0.43) TAS1R3TAS1R1CTSKCTSLCTSB
SCHEMBL6586343 0.94 TAS1R3 (0.43) TAS1R3TAS1R1CTSKCTSLCTSB
SCHEMBL4769990 0.91 TAS1R3 (0.50) TAS1R3TAS1R1CTSKCTSLCTSS
SCHEMBL4765650 0.91 TAS1R3 (0.50) TAS1R3TAS1R1CTSKCTSLCTSS
SCHEMBL4767072 0.90 TAS1R3 (0.38) TAS1R3TAS1R1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320370-A4 METHOD OF TREATMENT SMITHKLINE BEECHAM CORP (US) 2008-10-22 EP disclosed
EP-1307204-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2004-06-02 EP disclosed
EP-1320370-A1 METHOD OF TREATMENT SmithKline Beecham Corporation (US) 2003-06-25 EP disclosed
EP-1307204-A1 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2003-05-07 EP disclosed
WO-2002017924-A1 METHOD OF TREATMENT SMITHKLINE BEECHAM CORPORATION (GB) 2002-03-07 WO disclosed
WO-2001095911-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-12-20 WO disclosed